U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Pleas note: we will be discontinuing the Global Markets Report after 28 February. Australian shares are set to open lower, ...

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the stock market. When investing, your capital is at risk. The value of your ...

Franklin Resources (BEN) was the top performer in the S ... and raised its long-term sales outlook for the drugs. Vertex Pharmaceuticals (VRTX) moved up by 5.3% after it said that the Food and ...

Real-time index price for Dow Jones Transportations Average (DOWT), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Yahoo Finance Washington correspondent Ben Werschkul discusses the latest ... revenue guidance for new drugs Skyrizi and Rinvoq. Vertex Pharmaceuticals (VRTX) stock is rising after receiving ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...